Evidence map›Paper›PMID 30465934›Full record

ArticleArchives of oral biology2019

Enhanced basal autophagy supports ameloblastoma-derived cell survival and reactivation.

Rachel C Sharp, Olajumoke A Effiom, Anuradha Dhingra, Onatolu Odukoya, Adetokunbo Olawuyi, Godwin T Arotiba, Kathleen Boesze-Battaglia, Sunday O Akintoye

Open access · greenAbstract read
In one paragraph

Article in Archives of oral biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Cancers · 2022
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Rachel C SharpDepartment of Biochemistry, School of Dental Medicine, University of Pennsylvania, Philadelphia PA USA.
Olajumoke A EffiomDepartment of Oral and Maxillofacial Pathology/Biology, Faculty of Dental Sciences, University of Lagos, Lagos Nigeria.
Anuradha DhingraDepartment of Biochemistry, School of Dental Medicine, University of Pennsylvania, Philadelphia PA USA.
Onatolu OdukoyaDepartment of Oral and Maxillofacial Pathology/Biology, Faculty of Dental Sciences, University of Lagos, Lagos Nigeria.
Adetokunbo OlawuyiDepartment of Oral and Maxillofacial Pathology/Biology, Faculty of Dental Sciences, University of Lagos, Lagos Nigeria.
Godwin T ArotibaDepartment of Oral and Maxillofacial Surgery, Faculty of Dental Sciences, University of Lagos, Lagos Nigeria.
Kathleen Boesze-BattagliaDepartment of Biochemistry, School of Dental Medicine, University of Pennsylvania, Philadelphia PA USA.
Sunday O AkintoyeDepartment of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia PA USA. Electronic address: akintoye@upenn.edu.
University of Lagos · NGUniversity of Pennsylvania · US

Funding

Lysosomal maturation during periodontal infectionsR01DE022465 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI BOESZE-BATTAGLIA, KATHLEEN · 2012 to 2016
$2.0M
NIDCR NIH HHS R01 DE022465
6 · The paper itself

Abstract

objectivesAmeloblastoma is an aggressive odontogenic jaw neoplasm. Its unlimited growth confers high potential for malignant transformation and recurrence. It is unclear why ameloblastoma is highly recurrent despite surgical resection with a wide margin of normal tissue. While canonical autophagy can be used to degrade and eliminate damaged cellular components, it is also a protective mechanism that provides energy and vital metabolites for cell survival. We used ameloblastoma-derived cells to test the hypothesis that autophagic processes play a role in survival and reactivation of ameloblastoma.

methodsPrimary epithelial (EP-AMCs) and mesenchymal (MS-AMCs) ameloblastoma-derived cells were established from tissue samples of solid multicystic ameloblastoma. Clonogenic capacity and basal autophagic capacity were assessed in ameloblastoma-derived cells relative to human odontoma-derived cells (HODCs) and maxilla-mesenchymal stem cells (MX-MSCs). Ability of ameloblastoma-derived cells to survive and form new ameloblastoma was assessed in mouse tumor xenografts.

resultsEP-AMCs were highly clonogenic (p < 0.0001) and demonstrated enhanced basal levels of autophagic proteins microtubule-associated protein 1-light chain 3 (LC3) (p < 0.01), p62 (Sequestosome 1, SQSTM1) (p < 0.01), and the LC3-adapter, melanoregulin (MREG) (p < 0.05) relative to controls. EP-AMCs xenografts regenerated solid ameloblastoma-like tumor with histological features of columnar ameloblast-like cells, loose stellate reticulum-like cells and regions of cystic degeneration characteristic of follicular variant of solid multicystic ameloblastoma. The xenografts also displayed stromal epithelial invaginations strongly reactive to LC3 and p62 suggestive of epithelial-mesenchymal transition and neoplastic odontogenic epithelium.

conclusionsEP-AMCs exhibit altered autophagic processes that can support survival and recurrence of post-surgical ameloblastoma cells.

Indexed as

AmeloblastomaCell SurvivalOdontogenic TumorsAdaptor Proteins, Vesicular TransportAmeloblastsAnimalsAutophagyCarrier ProteinsDisease Models, AnimalEpithelial-Mesenchymal TransitionEpitheliumFemaleHeterograftsHumansIntracellular Signaling Peptides and ProteinsMesenchymal Stem CellsAdaptor Proteins, Vesicular TransportCarrier ProteinsIntracellular Signaling Peptides and ProteinsMap1lc3b protein, mousemelanoregulin protein, mouseMicrotubule-Associated ProteinsSequestosome-1 ProteinSqstm1 protein, mouseAmeloblastomaAutophagyRecurrenceSurvival

Identifiers

PMID30465934
PMCPMC6447039
OpenAlexW2900985581

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.